ZIM Board of Directors Appoints Dr. Chen Lichtenstein as President and CEO of the Company; will also be joining its Board of Directors

Rhea-AI Summary

ZIM (NYSE: ZIM) appointed Dr. Chen Lichtenstein as President and CEO, effective July 1, 2026, following the April 15, 2026 resignation of Eli Glickman.

He will also join the Board, with his employment agreement subject to shareholder approval under Israeli Companies Law.

Positive

• Appointment of experienced global executive as President and CEO effective July 1, 2026
• New CEO will also join ZIM’s Board of Directors on effective date
• Background as CFO of Syngenta Group with responsibility for strategy and integration
• Previous CEO experience at ADAMA during a period of growth and improved profitability

Negative

• Leadership transition following resignation of prior President and CEO on April 15, 2026
• CEO employment agreement still requires shareholder approval under Israeli Companies Law

News Market Reaction – ZIM

+5.24%

+5.24% Session close to close

In the Jun 1 session, ZIM gained 5.24%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAIFA, Israel, June 1, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) ("ZIM" or the "Company"), a global container liner shipping company, announced today the appointment of Dr. Chen Lichtenstein as its new President and Chief Executive Officer following the resignation on April 15, 2026, of Eli Glickman, the existing President and Chief Executive Officer. The appointment of Dr. Lichtenstein will become effective as of July 1, 2026, at which time Dr. Lichtenstein will also become a member of the Board of Directors of the Company. The employment agreement between the Company and Dr. Lichtenstein will be brought to shareholder approval as required by the Israeli Companies Law of 1999.

Dr. Lichtenstein brings with him extensive management, business and financial experience in the global arena, including leading complex international companies, managing growth processes, integration and organizational change, operating in international markets and working with boards of directors, shareholders and global investment bodies.

From 2020 to 2023, he served as the Chief Financial Officer at Syngenta Group, a global agricultural technology company, and was also responsible for strategy, integration and productivity. In this role, he was a key partner in building the global group, which included Syngenta Seeds, Syngenta Crop Protection, ADAMA and the Group's operations in China, and led significant steps towards growth, synergies, efficiency and management of a complex debt structure. Prior to his position at Syngenta Group, Dr. Lichtenstein served as the President and CEO of ADAMA Ltd. (formerly known as Makhteshim Agan Industries Ltd.) from 2014 to 2020, which he led during a period of significant, industry-leady growth, improved profitability and cash flow, integration with ChemChina's operations, and a listing on the Shenzhen Stock Exchange. From 2013 to 2014, Dr. Lichtenstein also served as President and CEO of China National Agrochemical Corporation, ChemChina's strategic agrochemical division, and parent of Syngenta Group. From 2006 to 2013 he served as the Deputy Chief Executive Officer, Head of Global Operations and held various other roles within Makhteshim Agan Industries, where he led, among other things, broad areas of activity including global operations, business development, integration in China, R&D, supply chain, purchasing and manufacturing. Previously Dr. Lichtenstein served as a senior investment banking executive at Goldman Sachs in New York and London from 1999 to 2006, where he led acquisition and financing transactions of significant scope.

Dr. Lichtenstein currently serves as a member of the Board of Directors at Teva Pharmaceuticals Ltd., as chairman of the board of directors at international companies in the fields of environmental sciences and biotechnology and as a senior advisor to international investment entities. Dr. Lichtenstein holds joint doctoral degrees from the Graduate School of Business and the School of Law at Stanford University, a B.Sc. in Physics from the Faculty of Mathematics and Natural Sciences, summa cum laude, and an LL.B. from the Faculty of Law, cum laude, at the Hebrew University of Jerusalem.

Dr. Lichtenstein was appointed following a search process, which was conducted on behalf of the ZIM Board of Directors, with the participation of the directors Yair Seroussi, the Chairman of the Board, Dr. Yoram Turbowicz and Yair Avidan.

Yair Seroussi, Chairman of the Board, stated, "Dr. Chen Lichtenstein is a highly experienced top-tier international executive, with a unique combination of extensive managerial experience, financial depth, strategic insight, and the ability to lead complex global organizations. His broad experience in managing international companies, working with global markets, shareholders, and boards of directors, together with his judgment and experience in leading transformation and integration processes, make him the right executive to lead ZIM at this time. We thank Eli Glickman for his significant contribution to the Company and wish Chen great success in his role."

Dr. Lichtenstein, ZIM President and CEO-appointee stated, "I thank ZIM's Board of Directors for its confidence and for the opportunity to lead a global Israeli company with a meaningful legacy, growth and business success, broad international operations, and outstanding people. ZIM operates in a dynamic, competitive, and complex market, and I attach great importance to maintaining the Company's stability, strengthening its performance and business capabilities, and continuing to create value for customers, employees, partners, and shareholders."

About ZIM

Founded in Israel in 1945, ZIM (NYSE: ZIM) is a leading global container liner shipping company with operations in more than 90 countries, serving over 30,000 customers across more than 300 ports worldwide. ZIM leverages digital strategies and a commitment to ESG values to provide customers innovative seaborne transportation and logistics services and exceptional customer experience. ZIM's differentiated global-niche strategy, based on agile fleet management and deployment, covers major trade routes with a focus on select markets where the company holds competitive advantages. Additional information about ZIM is available at www.ZIM.com.

Investor Relations:
Elana Holzman
ZIM Integrated Shipping Services Ltd.
+972-4-865-2300
holzman.elana@zim.com

Leon Berman
The IGB Group
212-477-8438
lberman@igbir.com

Media:
Avner Shats
ZIM Integrated Shipping Services Ltd.
+972-4-865-2520
media@zim.com

Logo: https://mma.prnewswire.com/media/1933864/ZIM_Logo.jpg 

 

View original content:https://www.prnewswire.com/news-releases/zim-board-of-directors-appoints-dr-chen-lichtenstein-as-president-and-ceo-of-the-company-will-also-be-joining-its-board-of-directors-302786894.html

SOURCE ZIM Integrated Shipping Services Ltd.

FAQ

Who is the new CEO of ZIM (NYSE: ZIM) and when does he start?

ZIM appointed Dr. Chen Lichtenstein as its new President and CEO, effective July 1, 2026. According to ZIM, he will also join the Board on that date, following Eli Glickman’s April 15, 2026 resignation.

What is Dr. Chen Lichtenstein’s professional background before becoming ZIM CEO?

Dr. Chen Lichtenstein previously served as CFO of Syngenta Group and CEO of ADAMA. According to ZIM, his roles covered global strategy, integration, productivity, growth, profitability, cash flow, China operations and listing ADAMA on the Shenzhen Stock Exchange.

Does ZIM’s new CEO appointment require shareholder approval?

Yes, ZIM’s employment agreement with Dr. Chen Lichtenstein is subject to shareholder approval. According to ZIM, this approval is required under the Israeli Companies Law of 1999 and applies to the terms of his employment as President and CEO.

Why did ZIM appoint a new President and CEO in 2026?

ZIM appointed a new President and CEO following Eli Glickman’s resignation on April 15, 2026. According to ZIM, the Board-led search process selected Dr. Chen Lichtenstein for his international management experience, financial depth and background in leading complex global organizations.

Will ZIM’s new CEO also serve on the Board of Directors?

Yes, Dr. Chen Lichtenstein will join ZIM’s Board of Directors when he becomes CEO on July 1, 2026. According to ZIM, his Board role aligns with his appointment as President and Chief Executive Officer of the company.

What are Dr. Chen Lichtenstein’s stated priorities as ZIM’s incoming CEO?

Dr. Chen Lichtenstein emphasizes maintaining ZIM’s stability and strengthening performance and business capabilities. According to ZIM, he also highlights creating value for customers, employees, partners and shareholders in a dynamic, competitive and complex container shipping market.